- Therapeutic Effect of Levodopa/Carbidopa/Entacapone on Sleep Disturbance in Patients with Parkinson’s Disease
-
Kye Won Park, Sungyang Jo, Seung Hyun Lee, Yun Su Hwang, Dagyo Lee, Ho-Sung Ryu, Sun Ju Chung
-
J Mov Disord. 2020;13(3):205-212. Published online September 9, 2020
-
DOI: https://doi.org/10.14802/jmd.20055
-
-
8,942
View
-
302
Download
-
12
Web of Science
-
14
Crossref
-
Abstract
PDF
- Objective
To investigate the efficacy of levodopa/carbidopa/entacapone (LCE) at bedtime for treating sleep disturbance in patients with Parkinson’s disease (PD) with motor fluctuations.
Methods Participants included 128 PD patients with motor fluctuations. All patients were assessed for motor, nonmotor, and sleep-specific symptoms using the United Parkinson’s Disease Rating Scale (UPDRS), the Korean version of the Nonmotor Symptom Scale, the Parkinson’s Disease Sleep Scale (PDSS), the Epworth Sleepiness Scale, and the Rapid Eye Movement Sleep Behavior Disorder Screening Questionnaire (RBDSQ). We compared the baseline characteristics of patients with sleep disturbance (PDSS score < 120) and those without sleep disturbance (PDSS score ≥ 120). Thirty-nine patients with sleep disturbance who agreed to take LCE at bedtime completed 3-month follow-ups. We analyzed changes in the scores of motor, nonmotor, and sleep symptom scales over the 3 months.
Results PD patients with sleep disturbance were at more advanced disease stages and had more severe motor, nonmotor, and sleep symptoms than those without sleep disturbance. Patients who took LCE at night showed improvements in motor (UPDRS part III, p = 0.007) and sleep symptoms (total PDSS, p < 0.001). Sleep features that benefitted from LCE included not only nocturnal motor components but also insomnia (PDSS items 2 and 3, p = 0.005 and p < 0.001) and rapid eye movement behavior disorder (PDSS item 6, p = 0.002; and RBDSQ, p < 0.001).
Conclusion The use of LCE at bedtime may be a useful treatment for sleep disturbance in advanced PD patients with motor fluctuations.
-
Citations
Citations to this article as recorded by 
- Diagnosis and treatment of autonomic failure, pain and sleep disturbances in Parkinson’s disease: guideline “Parkinson’s disease” of the German Society of Neurology
Alessandra Fanciulli, Friederike Sixel-Döring, Carsten Buhmann, Florian Krismer, Wiebke Hermann, Christian Winkler, Dirk Woitalla, Wolfgang H. Jost, Mathias Bähr, Jos Becktepe, Daniela Berg, Kathrin Brockmann, Andrés Ceballos-Baumann, Joseph Claßen, Corne Journal of Neurology.2025;[Epub] CrossRef - Comparison of sleep characteristics between Parkinson's disease with and without freezing of gait: A systematic review
Tracy Milane, Clint Hansen, Mathias Baptiste Correno, Matthias Chardon, Fabio A. Barbieri, Edoardo Bianchini, Nicolas Vuillerme Sleep Medicine.2024; 114: 24. CrossRef - Sleep and sleep disorders in people with Parkinson's disease
Alex Iranzo, Valerie Cochen De Cock, María Livia Fantini, Laura Pérez-Carbonell, Lynn Marie Trotti The Lancet Neurology.2024; 23(9): 925. CrossRef - Pharmacokinetics and Dose Proportionality Study of a Novel Antiparkinsonian Agent, a 1H-1,2,4-Triazol-3-ylthio-conjugate of Prottremine
Daria S. Gorina, Anastasiya V. Lastovka, Artem D. Rogachev, Alexandra V. Podturkina, Alla V. Pavlova, Oleg V. Ardashov, Nikolai S. Li-Zhulanov, Tatyana G. Tolstikova, Konstantin P. Volcho, Nariman F. Salakhutdinov Molecules.2024; 29(18): 4498. CrossRef - Opicapone versus entacapone: Head‐to‐head retrospective data‐based comparison of healthcare resource utilization in people with Parkinson's disease new to catechol‐O‐methyltransferase (COMT) inhibitor treatment
Glynn Harrison‐Jones, Xiaocong Li Marston, Francesca Morgante, K. Ray Chaudhuri, Guillermo Castilla‐Fernández, Valentina Di Foggia European Journal of Neurology.2023; 30(10): 3132. CrossRef - Management of REM sleep behavior disorder: an American Academy of Sleep Medicine systematic review, meta-analysis, and GRADE assessment
Michael Howell, Alon Y. Avidan, Nancy Foldvary-Schaefer, Roneil G. Malkani, Emmanuel H. During, Joshua P. Roland, Stuart J. McCarter, Rochelle S. Zak, Gerard Carandang, Uzma Kazmi, Kannan Ramar Journal of Clinical Sleep Medicine.2023; 19(4): 769. CrossRef - The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson’s disease: opicapone versus entacapone
Valentina Leta, Daniel J. van Wamelen, Federico Aureli, Vinod Metta, Dhaval Trivedi, Pietro Cortelli, Carmen Rodriguez-Blazquez, Alexandra Rizos, K. Ray Chaudhuri Journal of Neural Transmission.2023; 130(7): 925. CrossRef - Non-oral continuous drug delivery based therapies and sleep dysfunction in Parkinson’s disease
P. Tall, M. A. Qamar, L. Batzu, V. Leta, C. Falup-Pecurariu, K. Ray Chaudhuri Journal of Neural Transmission.2023; 130(11): 1443. CrossRef - Tenuigenin promotes non-rapid eye movement sleep via the GABAA receptor and exerts somnogenic effect in a MPTP mouse model of Parkinson's disease
Di Zhang, Wenjing Zhang, Shumin Deng, Lu Liu, Hua Wei, Fenqin Xue, Hui Yang, Xiaomin Wang, Zheng Fan Biomedicine & Pharmacotherapy.2023; 165: 115259. CrossRef - Neurological Insights into Sleep Disorders in Parkinson’s Disease
Subramanian Thangaleela, Bhagavathi Sundaram Sivamaruthi, Periyanaina Kesika, Subramanian Mariappan, Subramanian Rashmi, Thiwanya Choeisoongnern, Phakkharawat Sittiprapaporn, Chaiyavat Chaiyasut Brain Sciences.2023; 13(8): 1202. CrossRef - Real‐world considerations regarding the use of the combination of levodopa, carbidopa, and entacapone (Stalevo®) in Parkinson's disease
Heinz Reichmann European Journal of Neurology.2023; 30(S2): 15. CrossRef - Clinical profile of levodopa-carbidopa-entacapone intestinal gel infusion in patients with advanced Parkinson’s disease
Karina A. Atanasova-Ivanova, Sonya Ivanova Hristova-Chakmakova, Ivan G. Milanov Folia Medica.2023; 65(6): 929. CrossRef - The Home-Based Sleep Laboratory
Yael Hanein, Anat Mirelman, Anat Mirelman, E. Ray Dorsey, Patrik Brundin, Bastiaan R. Bloem Journal of Parkinson's Disease.2021; 11(s1): S71. CrossRef - Shudi Pingchan Decoction combined with repetitive transcranial magnetic stimulation in the treatment of Parkinson’s disease with sleep disorders
Qing Ye, Xiqun Chen, Yuqing Hu, Jie Zhou, Chen Gao, Zhenguo Liu Traditional Medicine and Modern Medicine.2020; 03(02): 85. CrossRef
- Fragile X-Associated Tremor/Ataxia Syndrome: An Illustrative Case
-
Chaewon Lee, Kye Won Park, Nari Choi, Ho-Sung Ryu, Sun Ju Chung
-
J Mov Disord. 2019;12(3):184-186. Published online July 17, 2019
-
DOI: https://doi.org/10.14802/jmd.18060
-
-
6,385
View
-
125
Download
-
2
Web of Science
-
4
Crossref
-
PDF
-
Citations
Citations to this article as recorded by 
- Exacerbation of Fragile X-associated Tremor/Ataxia Syndrome in the Context of COVID-19 Infection: A Case Report
Hussein Ghasham, Heather Heild, Rebecca Patel Cureus.2024;[Epub] CrossRef - Clinical Reasoning: A 50-Year-Old Man With Ataxia, Dystonia, and Abnormal Ocular Movements
Baikuntha Panigrahi, Divya Madathiparambil Radhakrishnan, Arti Saini, Venugopalan Y. Vishnu, Anu Gupta, Awadh Kishor Pandit, Ayush Agarwal, Divyani Garg, Mamta Bhushan Singh, Rohit Bhatia, Padma Srivastava, Achal Kumar Srivastava, Roopa Rajan Neurology.2024;[Epub] CrossRef - A Case of Fragile-X-Associated Tremor/Ataxia Syndrome Without Tremor
Woong-Woo Lee, Byung-Kun Kim, Jung Ju Lee, Kyusik Kang Journal of Clinical Neurology.2023; 19(5): 498. CrossRef - Brain 18F-FDG and 18F-Flumetamol PET Imaging of Fragile X-Associated Tremor Ataxia Syndrome
Ruggero Bacchin, Matteo Salgarello, Michela Trentin, Giampietro Zanette, Stefano Tamburin Clinical Nuclear Medicine.2021; 46(7): e344. CrossRef
- Sleepiness and Depression in Parkinson’s Disease Patients Treated with Ropinirole and Levodopa
-
Suk Yun Kang, Ho-Sung Ryu, Mun-Kyung Sunwoo, Sang-Jin Kim, Jong-Sam Baik, Mee-Young Park, Hyung-Eun Park, Joong-Seok Kim, Kyum-Yil Kwon, Seong-Beom Koh, Young-Eun Kim, Mi-Kyong Lee, Jong-Min Kim, Sun Ju Chung, Young-Ho Sohn
-
J Mov Disord. 2017;10(3):123-129. Published online September 22, 2017
-
DOI: https://doi.org/10.14802/jmd.17048
-
-
10,135
View
-
195
Download
-
12
Web of Science
-
10
Crossref
-
Abstract
PDF
- Objective
We aimed to investigate the effect of ropinirole on excessive daytime sleepiness (EDS) and depression in Parkinson’s disease (PD) with a large population.
Methods
We conducted a cross-sectional observational study at nine hospitals in Korea between April 24, 2013, and April 22, 2015. We analyzed the demographic and clinical features, other medical history, history of antiparkinsonian medication within 6 months, Hoehn and Yahr stage (HY stage), Unified Parkinson’s Disease Rating Scale (UPDRS) part II and III, Epworth Sleepiness Scale (ESS), and 30-item Geriatric Depression Scale (GDS-30).
Results
Four-hundred-thirteen patients with PD (mean age: 65.2 ± 9.0 years; men: 227 patients) were analyzed. Multivariate logistic regression analysis showed that age at examination, UPDRS II, and GDS-30 were independent risk factors for EDS and that sex, UPDRS II, and ESS were independent risk factors for depression.
Conclusion
Our large group study did not find any significant associations of ropinirole with EDS and depression in Korean PD patients.
-
Citations
Citations to this article as recorded by 
- Associations between non-motor symptoms and patient characteristics in Parkinson’s disease: a multicenter cross-sectional study
Remi Morimoto, Mutsumi Iijima, Yasuyuki Okuma, Keisuke Suzuki, Fumihito Yoshii, Shigeru Nogawa, Takashi Osada, Kazuo Kitagawa Frontiers in Aging Neuroscience.2023;[Epub] CrossRef - Excessive Daytime Sleepiness in Parkinson’s Disease
Hanshu Liu, Jingwen Li, Xinyi Wang, Jinsha Huang, Tao Wang, Zhicheng Lin, Nian Xiong Nature and Science of Sleep.2022; Volume 14: 1589. CrossRef - Excessive daytime sleepiness in Parkinson's disease: A systematic review and meta-analysis
Fei Feng, YingYing Cai, YanBing Hou, Ruwei Ou, Zheng Jiang, HuiFang Shang Parkinsonism & Related Disorders.2021; 85: 133. CrossRef - Sleep Disorders and Cognitive Dysfunctions in Parkinson’s Disease: A Meta-Analytic Study
Gianpaolo Maggi, Luigi Trojano, Paolo Barone, Gabriella Santangelo Neuropsychology Review.2021; 31(4): 643. CrossRef - Longitudinal risk factors for developing depressive symptoms in Parkinson's disease
Tarek Antar, Huw R. Morris, Faraz Faghri, Hampton L. Leonard, Mike A. Nalls, Andrew B. Singleton, Hirotaka Iwaki Journal of the Neurological Sciences.2021; 429: 117615. CrossRef - The effect and safety of ropinirole in the treatment of Parkinson disease
Jiali Zhu, Min Chen Medicine.2021; 100(46): e27653. CrossRef - Pramipexole regulates depression-like behavior via dopamine D3 receptor in a mouse model of Parkinson’s disease
Shi-Zhuang Wei, Xiao-Yu Yao, Chen-Tao Wang, An-Qi Dong, Dan Li, Yu-Ting Zhang, Chao Ren, Jin-Bao Zhang, Cheng-Jie Mao, Fen Wang, Chun-Feng Liu Brain Research Bulletin.2021; 177: 363. CrossRef - A selective D2 dopamine receptor agonist alleviates depression through up-regulation of tyrosine hydroxylase and increased neurogenesis in hippocampus of the prenatally stressed rats
Mahino Fatima, Mir Hilal Ahmad, Saurabh Srivastav, Moshahid Alam Rizvi, A.C. Mondal Neurochemistry International.2020; 136: 104730. CrossRef - ‘Dopamine agonist Phobia’ in Parkinson’s disease: when does it matter? Implications for non-motor symptoms and personalized medicine
Silvia Rota, Iro Boura, Lucia Batzu, Nataliya Titova, Peter Jenner, Cristian Falup-Pecurariu, K Ray Chaudhuri Expert Review of Neurotherapeutics.2020; 20(9): 953. CrossRef - An Investigation on the Clinical Features and Neurochemical Changes in Parkinson's Disease With Depression
Teng-Hong Lian, Peng Guo, Li-Jun Zuo, Yang Hu, Shu-Yang Yu, Li Liu, Zhao Jin, Qiu-Jin Yu, Rui-Dan Wang, Li-Xia Li, Ying-Shan Piao, Wei Zhang Frontiers in Psychiatry.2019;[Epub] CrossRef
- Oculodentodigital Dysplasia Presenting as Spastic Paraparesis: The First Genetically Confirmed Korean Case and a Literature Review
-
Kye Won Park, Ho-Sung Ryu, Juyeon Kim, Sun Ju Chung
-
J Mov Disord. 2017;10(3):149-153. Published online September 22, 2017
-
DOI: https://doi.org/10.14802/jmd.17050
-
-
7,648
View
-
139
Download
-
6
Web of Science
-
4
Crossref
-
Abstract
PDF Supplementary Material
- Oculodentodigital dysplasia (ODDD) is a rare autosomal dominant inherited disease caused by mutations of the human gap junction alpha 1 gene, which encodes the protein Connexin-43. Patients with ODDD may present with neurological deficits with a typical pleiotropic combination of characteristic craniofacial, ophthalmological, phalangeal, and dental anomalies. In this report, we describe the first genetically confirmed Korean ODDD patient, who presented with spastic paraparesis. We will also review the neurological aspects of ODDD as reported in the literature.
-
Citations
Citations to this article as recorded by 
- Glial Connexins and Pannexins in the Healthy and Diseased Brain
Christian Giaume, Christian C. Naus, Juan C. Sáez, Luc Leybaert Physiological Reviews.2021; 101(1): 93. CrossRef - Oculodentodigital Dysplasia: A Case Report and Major Review of the Eye and Ocular Adnexa Features of 295 Reported Cases
Virang Kumar, Natario L. Couser, Arti Pandya Case Reports in Ophthalmological Medicine.2020; 2020: 1. CrossRef - Novel ocular findings in oculodentodigital dysplasia (ODDD): a case report and literature review
Zhirong Wang, Limei Sun, Panfeng Wang, Chonglin Chen, Aiyuan Zhang, Weiqing Wang, Xiaoyan Ding Ophthalmic Genetics.2019; 40(1): 54. CrossRef - Oculodentodigital Dysplasia: A Hypomyelinating Leukodystrophy with a Characteristic MRI Pattern of Brain Stem Involvement
I. Harting, S. Karch, U. Moog, A. Seitz, P.J.W. Pouwels, N.I. Wolf American Journal of Neuroradiology.2019; 40(5): 903. CrossRef
- Comparison of Pallidal and Subthalamic Deep Brain Stimulation in Parkinson’s Disease: Therapeutic and Adverse Effects
-
Ho-Sung Ryu, Mi-Sun Kim, Sooyeoun You, Mi-Jung Kim, Young Jin Kim, Juyeon Kim, Kiju Kim, Sun Ju Chung
-
J Mov Disord. 2017;10(2):80-86. Published online May 8, 2017
-
DOI: https://doi.org/10.14802/jmd.17001
-
-
9,047
View
-
266
Download
-
6
Web of Science
-
7
Crossref
-
Abstract
PDF Supplementary Material
- Objective
To compare the therapeutic and adverse effects of globus pallidus interna (GPi) and subthalamic nucleus (STN) deep brain stimulation (DBS) for the treatment of advanced Parkinson’s disease (PD).
Methods We retrospectively analyzed the clinical data of patients with PD who underwent GPi (n = 14) or STN (n = 28) DBS surgery between April 2002 and May 2014. The subjects were matched for age at surgery and disease duration. The Unified Parkinson’s Disease Rating Scale (UPDRS) scores and levodopa equivalent dose (LED) at baseline and 12 months after surgery were used to assess the therapeutic effects of DBS. Adverse effects were also compared between the two groups.
Results At 12 months, the mean changes in the UPDRS total and part I–IV scores did not differ significantly between the two groups. However, the subscores for gait disturbance/postural instability and dyskinesia were significantly more improved after GPi DBS than those after STN DBS (p = 0.024 and 0.016, respectively). The LED was significantly more reduced in patients after STN DBS than that after GPi DBS (p = 0.004). Serious adverse effects did not differ between the two groups (p = 0.697).
Conclusion The patients with PD showed greater improvement in gait disturbance/postural instability and dyskinesia after GPi DBS compared with those after STN DBS, although the patients had a greater reduction in LED after STN DBS. These results may provide useful information for optimal target selection for DBS in PD.
-
Citations
Citations to this article as recorded by 
- Long-term motor outcomes of deep brain stimulation of the globus pallidus interna in Parkinson's disease patients: Five-year follow-up
Yun Su Hwang, Sungyang Jo, Seung Hyun Lee, Nayoung Kim, Mi-Sun Kim, Sang Ryong Jeon, Sun Ju Chung Journal of the Neurological Sciences.2023; 444: 120484. CrossRef - The Role of Microelectrode Recording in Deep Brain Stimulation Surgery for Parkinson’s Disease: A Systematic Review and Meta-Analysis
R. Saman Vinke, Martin Geerlings, Ashok K. Selvaraj, Dejan Georgiev, Bastiaan R. Bloem, Rianne A.J. Esselink, Ronald H.M.A. Bartels Journal of Parkinson’s Disease.2022; 12(7): 2059. CrossRef - Motor Thalamic Deep Brain Stimulation Alters Cortical Activity and Shows Therapeutic Utility for Treatment of Parkinson’s Disease Symptoms in a Rat Model
Heidi R. Tucker, Emily Mahoney, Kainat Akhtar, Tzu-Jen Kao, Gianna Mamone, Saisree Mikkilineni, Maya Ravi, Hanel Watkins, Danielle-Lee Terrelonge, Caryn Martin, Kristen Unger, Gabrielle Kim, Kyra Fiber, Megan Gupta, Jonathan Indajang, Eliyahu M. Kochman, Neuroscience.2021; 460: 88. CrossRef - Current Knowledge on the Background, Pathophysiology and Treatment of Levodopa-Induced Dyskinesia—Literature Review
Michał Hutny, Jagoda Hofman, Aleksandra Klimkowicz-Mrowiec, Agnieszka Gorzkowska Journal of Clinical Medicine.2021; 10(19): 4377. CrossRef - Estimating Risk for Future Intracranial, Fully Implanted, Modular Neuroprosthetic Systems: A Systematic Review of Hardware Complications in Clinical Deep Brain Stimulation and Experimental Human Intracortical Arrays
Autumn J. Bullard, Brianna C. Hutchison, Jiseon Lee, Cynthia A. Chestek, Parag G. Patil Neuromodulation: Technology at the Neural Interface.2020; 23(4): 411. CrossRef - Long-term Effects of Bilateral Subthalamic Deep Brain Stimulation on Postural Instability and Gait Difficulty in Patients with Parkinson’s Disease
Hae-Won Shin, Mi Sun Kim, Sung Reul Kim, Sang Ryong Jeon, Sun Ju Chung Journal of Movement Disorders.2020; 13(2): 127. CrossRef - Treatment strategies in advanced Parkinson's disease: Review of the literature
Yıldız Değirmenci Cumhuriyet Medical Journal.2017; 39(3): 509. CrossRef
- Clinical Heterogeneity of Atypical Pantothenate Kinase-Associated Neurodegeneration in Koreans
-
Jae-Hyeok Lee, Jongkyu Park, Ho-Sung Ryu, Hyeyoung Park, Young Eun Kim, Jin Yong Hong, Sang Ook Nam, Young-Hee Sung, Seung-Hwan Lee, Jee-Young Lee, Myung Jun Lee, Tae-Hyoung Kim, Chul Hyoung Lyoo, Sun Ju Chung, Seong Beom Koh, Phil Hyu Lee, Jin Whan Cho, Mee Young Park, Yun Joong Kim, Young H. Sohn, Beom Seok Jeon, Myung Sik Lee
-
J Mov Disord. 2016;9(1):20-27. Published online January 25, 2016
-
DOI: https://doi.org/10.14802/jmd.15058
-
-
22,150
View
-
235
Download
-
21
Web of Science
-
17
Crossref
-
Abstract
PDF Supplementary Material
- Objective
Neurodegeneration with brain iron accumulation (NBIA) represents a group of inherited movement disorders characterized by iron accumulation in the basal ganglia. Recent advances have included the identification of new causative genes and highlighted the wide phenotypic variation between and within the specific NBIA subtypes. This study aimed to investigate the current status of NBIA in Korea.
Methods We collected genetically confirmed NBIA patients from twelve nationwide referral hospitals and from a review of the literature. We conducted a study to describe the phenotypic and genotypic characteristics of Korean adults with atypical pantothenate kinase-associated neurodegeneration (PKAN).
Results Four subtypes of NBIA including PKAN (n = 30), PLA2G6-related neurodegeneration (n = 2), beta-propeller protein-associated neurodegeneration (n = 1), and aceruloplasminemia (n = 1) have been identified in the Korean population. The clinical features of fifteen adults with atypical PKAN included early focal limb dystonia, parkinsonism-predominant feature, oromandibular dystonia, and isolated freezing of gait (FOG). Patients with a higher age of onset tended to present with parkinsonism and FOG. The p.R440P and p.D378G mutations are two major mutations that represent approximately 50% of the mutated alleles. Although there were no specific genotype-phenotype correlations, most patients carrying the p.D378G mutation had a late-onset, atypical form of PKAN.
Conclusions We found considerable phenotypic heterogeneity in Korean adults with atypical PKAN. The age of onset may influence the presentation of extrapyramidal symptoms.
-
Citations
Citations to this article as recorded by 
- Genetic Landscape of Dystonia in Asian Indians
Arti Saini, Inder Singh, Mukesh Kumar, Divya Madathiparambil Radhakrishnan, Ayush Agarwal, Divyani Garg, Arunmozhimaran Elavarasi, Rahul Singh, Vivek Chouhan, Sandeep, Anu Gupta, Venugopalan Yamuna Vishnu, Mamta Bhushan Singh, Rohit Bhatia, Ajay Garg, Ne Movement Disorders Clinical Practice.2025;[Epub] CrossRef - Typical pantothenate kinase-associated neurodegeneration caused by compound heterozygous mutations in PANK2 gene in a Chinese patient: a case report and literature review
Yilun Tao, Chen Zhao, Dong Han, Yiju Wei, Lihong Wang, Wenxia Song, Xiaoze Li Frontiers in Neurology.2023;[Epub] CrossRef - The first Vietnamese patient who presented late onset of pantothenate kinase-associated neurodegeneration diagnosed by whole exome sequencing: A case report
Van Khanh Tran, Chi Dung Vu, Hai Anh Tran, Nguyen Thi Kim Lien, Nguyen Van Tung, Nguyen Ngoc Lan, Huy Thinh Tran, Nguyen Huy Hoang Medicine.2023; 102(43): e34853. CrossRef - Genetic mutation spectrum of pantothenate kinase-associated neurodegeneration expanded by breakpoint sequencing in pantothenate kinase 2 gene
Dahae Yang, Sanghyun Cho, Sung Im Cho, Manjin Kim, Moon-Woo Seong, Sung Sup Park Orphanet Journal of Rare Diseases.2022;[Epub] CrossRef - Long-Term Outcomes of Deep Brain Stimulation in Pantothenate Kinase-Associated Neurodegeneration-Related Dystonia
Kyung Ah Woo, Han-Joon Kim, Seung-Ho Jeon, Hye Ran Park, Kye Won Park, Seung Hyun Lee, Sun Ju Chung, Jong-Hee Chae, Sun Ha Paek, Beomseok Jeon Journal of Movement Disorders.2022; 15(3): 241. CrossRef - Psychiatric symptoms in an adolescent reveal a novel compound heterozygous mutation of the PANK2 gene in the atypical PKAN syndrome
Luz María González Huerta, Sorina Gómez González, Jaime Toral López Psychiatric Genetics.2021; 31(3): 95. CrossRef - Rational Design of Novel Therapies for Pantothenate Kinase–Associated Neurodegeneration
Nivedita Thakur, Thomas Klopstock, Suzanne Jackowski, Enej Kuscer, Fernando Tricta, Aleksandar Videnovic, Hyder A. Jinnah Movement Disorders.2021; 36(9): 2005. CrossRef - Atypical Pantothenate Kinase-Associated Neurodegeneration with variable phenotypes in an Egyptian family
Ali S. Shalash, Thomas W. Rösler, Ibrahim Y. Abdelrahman, Hatem S. Abulmakarem, Stefanie H. Müller, Franziska Hopfner, Gregor Kuhlenbäumer, Günter U. Höglinger, Mohamed Salama Heliyon.2021; : e07469. CrossRef - Treatment Responsiveness of Parkinsonism in Atypical Pantothenate Kinase‐Associated Neurodegeneration
Jeanne Feuerstein, Caroline Olvera, Michelle Fullard Movement Disorders Clinical Practice.2020;[Epub] CrossRef - Diagnostic and clinical experience of patients with pantothenate kinase-associated neurodegeneration
Randall D. Marshall, Abigail Collins, Maria L. Escolar, H. A. Jinnah, Thomas Klopstock, Michael C. Kruer, Aleksandar Videnovic, Amy Robichaux-Viehoever, Colleen Burns, Laura L. Swett, Dennis A. Revicki, Randall H. Bender, William R. Lenderking Orphanet Journal of Rare Diseases.2019;[Epub] CrossRef - Intrafamilial variability and clinical heterogeneity in a family with PLA2G6-associated neurodegeneration
Jong Kyu Park, Jinyoung Youn, Jin Whan Cho Precision and Future Medicine.2019; 3(3): 135. CrossRef - On the complexity of clinical and molecular bases of neurodegeneration with brain iron accumulation
C. Tello, A. Darling, V. Lupo, B. Pérez‐Dueñas, C. Espinós Clinical Genetics.2018; 93(4): 731. CrossRef - Looking Deep into the Eye-of-the-Tiger in Pantothenate Kinase–Associated Neurodegeneration
J.-H. Lee, A. Gregory, P. Hogarth, C. Rogers, S.J. Hayflick American Journal of Neuroradiology.2018; 39(3): 583. CrossRef - Parkinson’s Disease and Metal Storage Disorders: A Systematic Review
Edward Botsford, Jayan George, Ellen Buckley Brain Sciences.2018; 8(11): 194. CrossRef - Atypical pantothenate kinase-associated neurodegeneration: Clinical description of two brothers and a review of the literature
S. Mahoui, A. Benhaddadi, W. Ameur El Khedoud, M. Abada Bendib, M. Chaouch Revue Neurologique.2017; 173(10): 658. CrossRef - Clinical rating scale for pantothenate kinase‐associated neurodegeneration: A pilot study
Alejandra Darling, Cristina Tello, María Josep Martí, Cristina Garrido, Sergio Aguilera‐Albesa, Miguel Tomás Vila, Itziar Gastón, Marcos Madruga, Luis González Gutiérrez, Julio Ramos Lizana, Montserrat Pujol, Tania Gavilán Iglesias, Kylee Tustin, Jean Pie Movement Disorders.2017; 32(11): 1620. CrossRef - Missions of <italic>Journal of Movement Disorders</italic>
Yun Joong Kim Journal of Movement Disorders.2016; 9(1): 1. CrossRef
|